Sugi Predict

Sugi Predict / Compounds / SCHEMBL245270

SCHEMBL245270

SCHEMBL245270

BrCc1ccc2nsnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 5/20 0.48
▸ PTPN1 P18031 2/20 0.43
▸ TXNRD1 Q16881 1/20 0.41
▸ TXNRD3 Q86VQ6 1/20 0.41
▸ TXNRD2 Q9NNW7 1/20 0.41
▸ KDM4E B2RXH2 5/20 0.38
▸ ALDH1A1 P00352 6/20 0.38
▸ L3MBTL1 Q9Y468 4/20 0.38
▸ MAPT P10636 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ BLM P54132 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ RECQL P46063 3/20 0.38
▸ POLB P06746 3/20 0.38
▸ THRB P10828 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ APAF1 O14727 1/20 0.38
▸ NR4A1 P22736 1/20 0.38
▸ PPARG P37231 1/20 0.36
▸ NCOA2 Q15596 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7548986 0.89 NPC1 (0.40) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL4682270 0.78 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL257319 0.78 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL5262949 0.78 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL5654842 0.77 ALDH1A1 (0.47) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL8712671 0.76 PTPN11 (0.30) PTPN11
SCHEMBL18821935 0.75 NQO2 (0.39) KDM4EALDH1A1L3MBTL1MAPTMEN1
SCHEMBL12595077 0.74 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL5657152 0.74 PTPN11 (0.44) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL8724132 0.74 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570642-B2 GLP-IR modulating compounds GILEAD SCIENCES, INC. (US) 2026-03-10 — — US disclosed
EP-4691554-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 — — EP disclosed
EP-4271672-B1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP disclosed
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 — — EP disclosed
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-01 — — US disclosed
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-20 — — US disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 — — US disclosed
CN-117279905-A Carboxy-benzimidazole GLP-1R modulating compounds 吉利德科学公司 2023-12-22 — — CN disclosed
EP-4271672-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-08 — — EP disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 — — US disclosed
WO-2002096907-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-05 — — WO disclosed
WO-2002050061-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-27 — — WO disclosed
US-20020007059-A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers ABBOTT LABORATORIES 2002-01-17 — — US disclosed
WO-2001070731-A1 DECAHYDRO-ISOQUINOLINES NOVARTIS AG (CH) 2001-09-27 — — WO disclosed
EP-1056743-A1 BENZAMINE DERIVATIVES MERCK PATENT GmbH (DE) 2000-12-06 — — EP disclosed
WO-1999031092-A1 BENZAMINE DERIVATIVES MERCK PATENT GMBH (DE) 1999-06-24 — — WO disclosed
WO-1998042709-A1 ENDOTHELIN-RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 1998-10-01 — — WO disclosed
EP-0863898-A1 ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GmbH (DE) 1998-09-16 — — EP disclosed
WO-1998027091-A1 ENDOTHELIN RECEPTOR ANTAGONISTS AS PESTICIDES MERCK PATENT GMBH (DE) 1998-06-25 — — WO disclosed
WO-1997019077-A1 ENDOTHELIN RECEPTOR ANTAGONISTS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1997-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11725000-B2 Apoptosis inhibitors BAX, SDHA, SDHB PTPN11 4098/4885PTPN1 3931/4885TXNRD1 547/4885
US-11858918-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 PTPN11 1028/4885PTPN1 925/4885TXNRD1 596/4885
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 PTPN11 1854/4885PTPN1 2136/4885TXNRD1 1953/4885
US-20020007059-A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers KCNJ2, KCNH1, KCNJ1 PTPN11 4724/4885PTPN1 4502/4885TXNRD1 777/4885
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 PTPN11 1028/4885PTPN1 925/4885TXNRD1 596/4885
US-12570642-B2 GLP-IR modulating compounds GLP1R, GIPR, GPR119 PTPN11 448/4885PTPN1 402/4885TXNRD1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.